[1] MCGUIRE D K, SHIH W J, COSENTINO F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis[J]. JAMA Cardiol, 2021, 6(2): 148-158. doi:  10.1001/jamacardio.2020.4511
[2] CAPARROTTA T M, GREENHALGH A M, OSINSKI K, et al. Sodium–glucose co-Transporter2 inhibitors(SGLT2i)exposure and outcomes in Type2 diabetes: a systematic review of population-based observational studies[J]. Diabetes Ther, 2021, 12(4): 991-1028.
[3] BLAU J E, TELLA S H, TAYLOR S I, et al. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data[J]. Diabetes Metab Res Rev, 2017, 33(8): 10.1002/dmrr. 2924.
[4] EVANS K. Diabetic ketoacidosis: update on management[J]. Clin Med, 2019, 19(5): 396-398. doi:  10.7861/clinmed.2019-0284
[5] 纪立伟. 关注钠-葡萄糖转运蛋白2抑制剂引起的非高血糖性酮症酸中毒[J]. 药物不良反应杂志, 2021, 23(6): 281-284. doi:  10.3760/cma.j.cn114015-20210515-00575
[6] 中华医学会糖尿病学分会, 朱大龙. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409.
[7] DANNE T, GARG S, PETERS A L, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors[J]. Diabetes Care, 2019, 42(6): 1147-1154. doi:  10.2337/dc18-2316
[8] COLLINS G S, REITSMA J B, ALTMAN D G, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement[J]. BMJ, 2015, 350: g7594. doi:  10.7326/l15-0078-4
[9] 贺彩红, 刘金武, 朱照贺, 等. 联合预测因子对急性心肌梗死患者院内并发1型心肾综合征风险的预测价值[J]. 中华心血管病杂志, 2021, 49(8): 802-808.
[10] MEYER E J, GABB G, JESUDASON D. SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a south Australian clinical case series and Australian spontaneous adverse event notifications[J]. Diabetes Care, 2018, 41(4): e47-e49. doi:  10.2337/dc17-1721
[11] SAMPANI E, SARAFIDIS P, PAPAGIANNI A. Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment[J]. Expert Opin Drug Saf, 2020, 19(6): 673-682. doi:  10.1080/14740338.2020.1764532
[12] HAYAMI T, KATO Y, KAMIYA H, et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet[J]. J Diabetes Investig, 2015, 6(5): 587-590.
[13] U. S. Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections[EB/OL].(2015-04-12)[2024-03-20]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious.
[14] YU X F, ZHANG S F, ZHANG L. Newer perspectives of mechanisms for euglycemic diabetic ketoacidosis[J]. Int J Endocrinol, 2018, 2018: 7074868. doi:  10.1155/2018/7074868
[15] ATA F, YOUSAF Z, KHAN A A, et al. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort[J]. Sci Rep, 2021, 11(1): 10293. doi:  10.1038/s41598-021-89752-w
[16] VALLON V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus[J]. Annu Rev Med, 2015, 66: 255-270. doi:  10.1146/annurev-med-051013-110046
[17] FERRANNINI E, BALDI S, FRASCERRA S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes[J]. Diabetes, 2016, 65(5): 1190-1195. doi:  10.2337/db15-1356
[18] LI N, ZHOU G W, ZHENG Y W, et al. Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: a meta-analysis[J]. PLoS One, 2022, 17(1): e0261986. doi:  10.1371/journal.pone.0261986
[19] PERRY R J, RABIN-COURT A, SONG J D, et al. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats[J]. Nat Commun, 2019, 10(1): 548. doi:  10.1038/s41467-019-08466-w
[20] GOLDENBERG R M, BERARD L D, CHENG A Y Y, et al. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis[J]. Clin Ther, 2016, 38(12): 2654-2664. e1.
[21] BAMGBOYE A O, ONI I O, COLLIER A. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review[J]. Eur J Clin Pharmacol, 2021, 77(5): 651-657. doi:  10.1007/s00228-020-03051-3
[22] QIU H Y, NOVIKOV A, VALLON V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives[J]. Diabetes Metab Res Rev, 2017, 33(5).
[23] 夏凌志, 李鹤. 血清降钙素原、C反应蛋白及中性粒细胞计数联合检测在儿童感染性肺炎中的应用评价[J]. 现代医药卫生, 2017, 33(22): 3460-3462. doi:  10.3969/j.issn.1009-5519.2017.22.033
[24] KAMEDA Y, KATO M, INOUE B, et al. Euglycemic diabetic ketoacidosis caused by a sodium-glucose co-transporter(SGLT)2 inhibitor after coronary artery bypass grafting[J]. Kyobu Geka, 2019, 72(5): 354-357. doi:  10.1016/s0735-1097(19)33029-3
[25] BURKE K R, SCHUMACHER C A, HARPE S E. SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature[J]. Pharmacotherapy, 2017, 37(2): 187-194. doi:  10.1002/phar.1881
[26] PACE D J, DUKLESKA K, PHILLIPS S, et al. Euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter 2 inhibitor use in two patients undergoing pancreatectomy[J]. J Pancreat Cancer, 2018, 4(1): 95-99. doi:  10.1089/pancan.2018.0016
[27] HANDELSMAN Y, HENRY R R, BLOOMGARDEN Z T, et al. American association of clinical endocrinologists and American college of endocrinology position statement on the association of sglt-2 inhibitors and diabetic ketoacidosis[J]. Endocr Pract, 2016, 22(6): 753762. doi:  10.4158/ep161292.ps
[28] LARROUMET A, CAMOIN M, FOUSSARD N, et al. Euglycemic ketoacidosis induced by therapeutic fasting in a non-diabetic patient[J]. Nutrition, 2020, 72: 110668. doi:  10.1016/j.nut.2019.110668